16/10/2014 08:42:21

EXINI to arrange Bone Scan Index (BSI) symposium at important annual European congress

Lund, Sweden, 2014-10-16 09:42 CEST (GLOBE NEWSWIRE) --

EXINI and FUJIFILM RI Pharma will arrange a Bone Scan Index (BSI) symposium on

October 20th at this year’s EANM-congress (European Association of Nuclear

Medicine) held in Gothenburg, October 18-22.

The symposium called ”Bone Scan Index (BSI) A Nuclear Medicine Biomarker in

Metastatic Prostate Cancer”, commence at 13.00 p.m. For more information >>

Program

”The symposium provide a unique opportunity for invited physicians within

nuclear medicine, to learn more about the imaging biomarker BSI and its

clinical applications. Arranging it together with our partner FUJIFILM RI

Pharma adds extensive clinical experience and insights gained from the success

of our product EXINI boneBSI (Bonenavi) on the Japanese market ”, comments

Magnus Aurell, CEO, EXINI Diagnostics AB.

Throughout the congress, several academic studies based upon use of the

software EXINI boneBSI and its BSI-calculating capacity, will be presented:

OP365: Prognostic value of bone scan index for treatment response and survival

in patients with high-risk prostate cancer. M. Reza, A. Bjartell, M. Ohlsson,

R. Kaboteh, P. Wollmer, L. Edenbrandt, E. Trägård

P491: Analytical validation of automated bone scan index as a candidate imaging

biomarker for advanced prostate cancer. A. Anand, L. Edenbrandt, A. Bjartell,

D. Minarik

P502: Reproducibility of automated bone scan index in patients with advanced

prostate cancer. A. Anand, L. Båth, R. Kaboteh, A. Bjartell, L. Edenbrandt

P786: Routine usefulness analysis of computer assisted diagnosis (CAD) software

for bone scan index L. Ferrer, M. Colombie, D. Rusu, D. Goulon, B. Jamet, N.

Varmenot, F. Kraeber-Bodere, C. Rousseau

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable

information to be used for diagnosis and stratification and the monitoring of

treatment response. It also provides increased accuracy in prognoses involving

patients suffering from skeletal metastases originating from prostate- or

breast cancer.

What is more, BSI has demonstrated its importance in the process of developing

new drugs, thus proving itself just as important for clinical use as for the

pharmaceutical industry. EXINI boneBSI is the only software capable of

extracting BSI-values for both these purposes.

www.bonescanindex.org

www.exini.com/software-bone-bsi/

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46 286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision

support to hospitals worldwide. The system is based on advanced image analysis

by artificial intelligence and can make its own interpretation of medical

images and provide diagnostic suggestions. In this way the system is used as a

decision support for the diagnosing doctor. EXINI is working with products for

the diagnosis of some of the most frequent endemic diseases such as cancer,

coronary heart disease, dementia and Parkinson's disease. The company was

founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock

market NASDAQ OMX First North and has about 600 shareholders. Principal owner

is Bo Håkansson. Consensus acts as Certified Adviser.

________________________________________________________________________

EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70

Lund, Sweden

Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com,

www.exini.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Feb
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker mine analyse af Pandoras forretnings..
80
10 Feb
I:SP500
Hejsa alle sammen   Så er det vinterferie og hvad kan tiden bruges til, ja lidt teknisk på stockmark..
36
13 Feb
 
Lad dog Henrik dø i fred i stedet for at komme med jeres dumsmarte bemærkninger   Det er upazsende u..
28
16 Feb
NOVO-B
@ Investor1 Jeg er hverken for eller imod hvad du skriver, men jeg har nu i gennem næsten et år løbe..
26
11 Feb
I:SP500
Prisdannelsen over S&P 500 med anvendelsen af candelstik med en månedlig tidsramme:   https://invst...
24
16 Feb
NOVO-B
Din og Investor1's totale fejlvurdering af både Zealand og Novo har desværre udviklet sig til et per..
19
15 Feb
OMXC20
Kære alle. Jeg har flere gange tilbudt at svare på investeringsspørgsmål for at bidrage til at så ma..
19
13 Feb
 
nu syntes jeg i er for åndsvage manden er ved at dø forhelvede
18
10 Feb
PNDORA
Jeg forstår ikke, hvordan man kan være så blæst i hovedet, som du er.
18
12 Feb
FING-B
Fjols
17

Elliott Capital Advisors, L.P : Form 8.3 - MELROSE INDUSTRIES PLC

16/02/2018 15:25:32
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners an..

Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers

16/02/2018 13:00:19
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management   SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of cu..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM plc

16/02/2018 10:19:24
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PHOTO RELEASE--Huntington Ingalls Industries Awarded $1.43 Billion Contract For The Construction of LPD 29
2
Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
3
QUANTUM CORPORATION SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Quantum Corporation - QTM
4
WELLS FARGO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Wells Fargo & Company - WFC
5
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Obalon Therapeutics, Inc. (OBLN)

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 February 2018 19:34:40
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180209.1 - EUROWEB4 - 2018-02-17 20:34:40 - 2018-02-17 19:34:40 - 1000 - Website: OKAY